Relapsed/Refractory Aggressive Mature B-cell Neoplasms research hub

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms

This study is looking at a new medicine called epcoritamab for children and young people with a type of aggressive blood cancer that has come back or not responded to previous treatments. The main goal is to check if the medicine is safe and how well the body handles it.